Opinion of the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking on the IMI2 JU Final Annual Accounts 2020

THE GOVERNING BOARD OF THE INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING (IMI2 JU),

Having regard to the Statutes annexed to the Council Regulation (EU) No 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking and in particular Articles 7.3, 9.4 and 17.3, Paragraph 4 thereof,

Having regard to the Financial Rules of the Innovative Medicines Initiative 2 Joint Undertaking adopted by the Governing Board on 27 May 2020 (IMI2-GB-DEC-2020-16), and in particular Article 52 paragraph 3 and Article 54 thereof,

Whereas:

2. The IMI2 JU has concluded a service level agreement with Directorate General for Budget for the provision of accounting services from 1 September 2015.
3. The IMI2 JU Accounting Officer has prepared and sent to the European Court of Auditors and to the European Commission the Provisional Annual Accounts 2020.
4. The European Court of Auditors considered the audit work performed by the independent external auditor.
5. On receiving the European Court of Auditors’ observations and unqualified opinion on provisional annual accounts, the Accounting Officer has drawn the final accounts of the IMI2 JU in accordance with standard Commission accounting policies and following the harmonised standard template.
6. The Governing Board should deliver an opinion on the IMI2 JU Final Annual Accounts 2020,

HAS DELIVERED:

a positive opinion on the annexed Final Annual Accounts 2020.

Brussels, on June 25, 2021.

For the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking

Olivier Laureau
Chairperson of the Governing Board

Annex: IMI2 JU Final Annual Accounts 2020